Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
In Vivo (Athens, Greece)
|
October 26, 2021
Paclitaxel and Carboplatin <i>Versus</i> Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer
Po-Hsu Su, Shun-Wen Hsueh, Chen-Kan Tseng, et al.
Cancer Medicine
|
February 9, 2024
The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis
Shih-Yu Huang, Po-Jung Su, Chang-Ting Lin, et al.
Journal of Cancer Research and Clinical Oncology
|
October 7, 2025
Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan
Wen-Kuan Huang, Po-Jung Su, Chun-Chi Chen, et al.
Therapeutic Advances in Medical Oncology
|
December 17, 2024
Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors
Liang-Yun Cheng, Po-Jung Su, Ming-Chun Kuo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 12, 2025
Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Yu-Chieh Tsai, Jian-Ri Li, Kun-Yuan Chiu, et al.
European Urology
|
June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
BMC Cancer
|
September 15, 2023
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
Tsung-Han Tsai, Po-Jung Su, Shih-Yu Huang, et al.
The Oncologist
|
November 20, 2024
Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer
Wen-Kuan Huang, Yan-Jei Tang, Chiao-En Wu, et al.
Cancer Medicine
|
October 27, 2021
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence
Jason Chia-Hsun Hsieh, Pin-Chun Chiang, Tsung-Min Hung, et al.
European Urology Oncology
|
May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial
Petros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
In Vivo (Athens, Greece)
|
October 26, 2021
Paclitaxel and Carboplatin <i>Versus</i> Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer
Po-Hsu Su, Shun-Wen Hsueh, Chen-Kan Tseng, et al.
Cancer Medicine
|
February 9, 2024
The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis
Shih-Yu Huang, Po-Jung Su, Chang-Ting Lin, et al.
Journal of Cancer Research and Clinical Oncology
|
October 7, 2025
Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan
Wen-Kuan Huang, Po-Jung Su, Chun-Chi Chen, et al.
Therapeutic Advances in Medical Oncology
|
December 17, 2024
Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors
Liang-Yun Cheng, Po-Jung Su, Ming-Chun Kuo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
April 12, 2025
Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Yu-Chieh Tsai, Jian-Ri Li, Kun-Yuan Chiu, et al.
European Urology
|
June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
BMC Cancer
|
September 15, 2023
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
Tsung-Han Tsai, Po-Jung Su, Shih-Yu Huang, et al.
The Oncologist
|
November 20, 2024
Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer
Wen-Kuan Huang, Yan-Jei Tang, Chiao-En Wu, et al.
Cancer Medicine
|
October 27, 2021
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence
Jason Chia-Hsun Hsieh, Pin-Chun Chiang, Tsung-Min Hung, et al.
European Urology Oncology
|
May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial
Petros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.
Page
of 5